Synaptogenix (NASDAQ:TAOX – Get Free Report) and Innoviva (NASDAQ:INVA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
Profitability
This table compares Synaptogenix and Innoviva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synaptogenix | -2,153.97% | -128.51% | -97.54% |
| Innoviva | 81.19% | 28.03% | 20.19% |
Earnings & Valuation
This table compares Synaptogenix and Innoviva”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synaptogenix | $300,000.00 | 95.74 | -$28.74 million | ($3.85) | -1.00 |
| Innoviva | $411.33 million | 3.73 | $271.17 million | $4.10 | 5.17 |
Innoviva has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Synaptogenix and Innoviva, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synaptogenix | 1 | 0 | 0 | 0 | 1.00 |
| Innoviva | 0 | 2 | 4 | 0 | 2.67 |
Innoviva has a consensus price target of $39.25, suggesting a potential upside of 85.05%. Given Innoviva’s stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than Synaptogenix.
Insider & Institutional Ownership
10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Synaptogenix has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Summary
Innoviva beats Synaptogenix on 11 of the 14 factors compared between the two stocks.
About Synaptogenix
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
About Innoviva
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
